BioSpace News Archive

Biorelate, the AI company curating biomedical knowledge, today announces the launch of its proprietary tool for accelerated research intelligence, Galactic, at BioData World West 2019.

Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com.

First and only Adenosine A2A receptor antagonist for use in Parkinson’s disease in the U.S.

Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) focused on hard-to-detect diseases, women’s health and infertility, announces the launch of FertilityDX™, a comprehensive genetic testing service that identifies barriers to healthy pregnancy and birth, allowing doctors to tailor fertility treatments.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced the appointment of Amy C. Peterson, M.D., as executive vice president and chief development officer

Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced that CEO, Shital Mars will be the keynote speaker at Cold Chain Global Forum in Boston, Massachusetts on October 15-18, 2019.

Fresenius Medical Care North America (FMCNA), the nation’s leading provider of kidney care products and services, released the following statement in response to the signing of AB 290 in California

Bongo® Rx, an FDA cleared medical device for the treatment of mild to moderate obstructive sleep apnea, utilizes no electricity or batteries.

Univfy®, an AI platform company whose mission is to improve fertility patients’ experience and access to in vitro fertilization (IVF), announced today a collaboration with BBVA USA, the US subsidiary of global financial institution BBVA, to offer a finance program with rates starting at 0% APR (up to 18.99%).

Children with asthma who are required to switch inhaler types to accommodate insurance formulary changes may experience a loss of lung function not seen in children whose inhaler type stayed the same, according to Scott Bickel, MD, from the University of Louisville School of Medicine, who will present the study findings at the CHEST Annual Meeting 2019 in New Orleans.